Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may cause severe life-threatening diseases called acute respiratory distress syndrome (ARDS) owing to cytokine storms. The mortality rate of COVID-19-related ARDS is as high as 40% to 50%. However, effective treatment for the ext...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2022-11, Vol.17 (11), p.e0277790-e0277790
Hauptverfasser:	Rahman, Motlabur, Datta, Ponkaj K, Islam, Khairul, Haque, Mahfuzul, Mahmud, Reaz, Mallik, Uzzwal, Hasan, Pratyay, Haque, Manjurul, Faruq, Imtiaz, Sharif, Mohiuddin, Ratul, Rifat H, Azad, Khan Abul Kalam, Miah, Titu, Rahman, Md Mujibur
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-inflammatory agents Bangladesh Biology and Life Sciences Clinical Deterioration Clinical trials Colchicine Colchicine - therapeutic use Coronaviruses COVID-19 COVID-19 Drug Treatment Cytokine Release Syndrome Cytokine storm Cytokines Domains Health hazards Health services Humans IL-1β Immune response Immunosuppressive agents Inflammation Interleukin 1 Leucine Mechanical ventilation Medicine and Health Sciences Mortality Nucleotides Oral administration Patients Pharmaceuticals Physical Sciences Placebos Pyrin protein Randomization Reduction Research and Analysis Methods Respiratory diseases Respiratory distress syndrome Respiratory Distress Syndrome - drug therapy SARS-CoV-2 Search engines Severe acute respiratory syndrome coronavirus 2 Statistical analysis Treatment Outcome Ventilation Viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!